Greater Cannabis (GCAN) Stock Price, News & Analysis

Company Overview

The Greater Cannabis Company, Inc. engages in the development and commercialization of cannabinoid therapeutics. It offers an oral transmucosal patch platform, which provides loaded actives absorbed by the buccal mucosa into the body. The company has a license agreement with Shaare Zedek Scientific Ltd. that focuses on treatment of autism, schizophrenia, Parkinson's disease, Alzheimer's disease, and other neuropsychiatric disorders. The Greater Cannabis Company, Inc. was founded in 2014 and is based in Baltimore, Maryland.

Key Stats

• Today's Range: $0.0001 to $0.0002
• 50-Day Range: N/A
• 52-Week Range: $0.0001 to $0.0024
• Volume: 524,500 shs
• Average Volume: 17.41 million shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

GCAN Stock Analysis - Frequently Asked Questions

How have GCAN shares performed this year?

Greater Cannabis' stock was trading at $0.0004 at the start of the year. Since then, GCAN shares have decreased by 50.0% and is now trading at $0.0002.

How do I buy shares of Greater Cannabis?

Shares of GCAN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Greater Cannabis own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Greater Cannabis investors own include Green Thumb Industries (GTBIF), Trulieve Cannabis (TCNNF), 22nd Century Group (XXII), Curaleaf (CURLF), Charlotte's Web (CWBHF), Planet 13 (PLNHF) and Alliance Resource Partners (ARLP).

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:GCAN
• CIK: 1695473
• Web: www.gcanrx.com
• Phone: (443) 738-4051
• Fax: N/A
• Employees: 1
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A